Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8463144 | 0.88 | GRM5 (0.43) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL29891425 | 0.88 | GRM5 (0.43) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL16122643 | 0.86 | GRM5 (0.42) | GRM5VCAM1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL31085124 | 0.84 | GRM5 (0.41) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL29686604 | 0.84 | GRM5 (0.41) | GRM5VCAM1TTRALBKCNJ6 | |
| SCHEMBL18795224 | 0.80 | GRM5 (0.38) | GRM5VCAM1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL12479768 | 0.80 | GRM5 (0.38) | GRM5VCAM1 | |
| SCHEMBL16398672 | 0.80 | GRM5 (0.41) | GRM5TTRALBMEN1KMT2A | |
| SCHEMBL9710858 | 0.78 | VCAM1 (0.39) | GRM5VCAM1TTRALBMEN1 | |
| SCHEMBL7931074 | 0.78 | VCAM1 (0.46) | VCAM1TTRALBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4952719-A | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1990-08-28 | — | — | US | claimed |
| EP-0180057-B1 | PROCESS FOR THE PREPARATION OF HALO AROMATIC COMPOUNDS | OCCIDENTAL CHEMICAL CORPORATION (US) | 1989-08-09 | — | — | EP | claimed |
| EP-0180057-A1 | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-05-07 | — | — | EP | claimed |
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-117209472-A | KIF18A inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3774774-B1 | PYRIDINE SUBSTITUTED 2,2'-DI-9H-CARBAZOL-9-YL-[1,1'-BIPHENYL]-DICARBONITRILE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20220119337-A1 | PROCESS FOR PREPARATION OF HALOGENATED BENZYLAMINE AND INTERMEDIATES THEROF | SRF LIMITED (IN) | 2022-04-21 | — | — | US | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3914582-A1 | PROCESS FOR PREPARATION OF HALOGENATED BENZYLAMINE AND INTERMEDIATES THEROF | SRF LIMITED (IN) | 2021-12-01 | — | — | EP | disclosed |
| EP-0180057-B1 | PROCESS FOR THE PREPARATION OF HALO AROMATIC COMPOUNDS | OCCIDENTAL CHEMICAL CORPORATION (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4590315-A | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-05-20 | — | — | US | disclosed |
| US-4590315-A | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-05-20 | — | — | US | disclosed |
| EP-0180057-A1 | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-05-07 | — | — | EP | disclosed |
| EP-0180057-A1 | Process for the preparation of halo aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-05-07 | — | — | EP | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119337-A1 | PROCESS FOR PREPARATION OF HALOGENATED BENZYLAMINE AND INTERMEDIATES THEROF | BTF3, BBOX1, TEAD1 | GRM5 3481/4885VCAM1 3882/4885TTR 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.